US 12,133,869 B2
Using autologous mesenchymal stem cells to treat multiple system atrophy
Wolfgang Singer, Rochester, MN (US); and Phillip Low, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Jun. 23, 2023, as Appl. No. 18/213,687.
Application 18/213,687 is a continuation of application No. 17/886,730, filed on Aug. 12, 2022, granted, now 11,723,928.
Application 17/886,730 is a continuation of application No. 15/736,644, granted, now 11,426,431, issued on Aug. 30, 2022, previously published as PCT/US2016/037632, filed on Jun. 15, 2016.
Claims priority of provisional application 62/175,628, filed on Jun. 15, 2015.
Prior Publication US 2024/0100097 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61P 25/28 (2006.01)
CPC A61K 35/28 (2013.01) [A61K 9/0085 (2013.01); A61P 25/28 (2018.01); A61K 2035/124 (2013.01)] 4 Claims
 
1. A method of treating a human having multiple system atrophy at a disease stage having a Unified Multiple System Atrophy Rating Scale I (UMSARS I) score of 17 or less, wherein said method comprises intrathecally administering, to said human that was identified as having multiple system atrophy with a first UMSARS I score, a composition comprising autologous mesenchymal stem cells, wherein said first UMSARS I score is 17 or less, and wherein, at least three months following said administering step, said human has a second UMSARS I score that is not greater than said first UMSARS I score.